Wirkung des standardisierten japanischen Kampo-Arzneipflanzenpräparates Juzentaihoto auf das Tumormikroenvironment des Pankreaskarzinoms – ein Vergleich mit Gemcitabin

Effect of the standardized Japanese Kampo Extract Juzen-taiho-to on the Tumor microenvironment in a Pancreatic cancer mouse model – a comparison to Gemcitabine

von Anna Paulina Siebel
Dissertation
Datum der mündl. Prüfung:2025-03-20
Erschienen:2025-02-24
Betreuer:PD Dr. Silke Cameron
Gutachter:Dr. Joanna Napp
Gutachter:Prof. Dr. Thomas Meyer
Zum Verlinken/Zitieren: http://dx.doi.org/10.53846/goediss-11104

 

 

Dateien

Name:2025_02_06_Siebel_Anna Paulina_Dissertation_...pdf
Size:36.4Mb
Format:PDF

Diese Datei ist bis 24.04.2025 gesperrt.

Zusammenfassung

Englisch

Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive gastrointestinal malignancies, characterized by poor prognosis and limited therapeutic success. Despite surgical resection being the sole curative approach, the high recurrence rate and late-stage diagnosis necessitate innovative therapeutic strategies. This study investigates the immunomodulatory effects of the standardized Japanese herbal medicine Juzentaihoto (JUZ) alone and in combination with gemcitabine, a standard chemotherapeutic agent, in an orthotopic pancreatic cancer mouse model and in vitro settings. The findings demonstrate that JUZ promotes M1 macrophage polarization, enhancing anti-tumor immune responses, while improving the efficacy of gemcitabine by mitigating its resistance. Additionally, JUZ significantly modulates the tumor microenvironment and cytokine expression, resulting in prolonged survival in treated groups. These results underline the potential of JUZ as an adjuvant therapy for PDAC, emphasizing the need for further molecular investigations and clinical trials to validate its application.
Keywords: Pancreatic ductal adenocarcinoma (PDAC); Kampo medicine; Juzentaihoto; Gemcitabine; orthotopic transplantation PDAC mouse model; murine KPC pancreatic tumor cells; macrophages; tumor microenvironment
Schlagwörter: Kampo Medizin; Juzentaihoto; Gemcitabin; Duktales Pankreaskarzinom; Makrophagen; Tumormikroenvironment